Background-Activator protein (AP) 2␣ negatively regulates expression of ABCA1 gene through Ser-phosphorylation of AP2␣ (Circ Res. 2007;101:156 -165). Potential specific Ser-phosphorylation sites for this reaction were investigated in human AP2␣. Methods and Results-The phosphorylation was shown mediated by PKD, and Ser258 and Ser326 were found in its specific phosphorylation sequence segment in AP2␣. PKD phosphorylated Ser258 more than Ser326 and induced its binding to the ABCA1 promoter. These reactions and AP2␣-induced suppression of the ABCA1 promoter activity were reversed by mutation of Ser258 more than Ser326 mutation. Knockdown of PKD by siRNA reduced the AP2␣ Ser-phosphorylation, and increased ABCA1 expression and HDL biogenesis. Gö6983 inhibited PKD more selectively than PKC in THP-1 and HEK 293 cells and in mice, and increased ABCA1 expression, HDL biogenesis, and plasma HDL level. Conclusion-PKD phosphorylates AP2␣ to negatively regulate expression of ABCA1 gene to increase HDL biogenesis.
W e recently reported that activator protein (AP) 2␣ negatively regulates expression of the ATP-binding cassette transporter (ABC) A1 gene, and inhibition of this system accordingly increases ABCA1 and high-density lipoprotein (HDL) biogenesis. 1 We proposed that serine (Ser)phosphorylation of AP2␣ is a candidate for a regulatory mechanism for its interaction with the ABCA1 promoter.
As illustrated in supplemental Figure I (available online at http://atvb.ahajournals.org), AP2␣ is reportedly phosphorylated by protein kinase A (PKA) at Ser239 in its basic domain for transactivation of the apolipoprotein (apo) E promoter, but its mutation to alanine (Ala) to abolish this phosphorylation did not influence the AP2␣ binding to the apoE promoter. 2 Therefore, the Ser-phosphorylation of AP2␣ to regulate its DNA binding should take place at other residue(s) than this. In addition to Ser239 in a PKA-phosphorylation motif RRXS/T (supplemental Figure IB) , 2 Ser258 and Ser326 were found consisting a segment LXRXXS/T, a phosphorylation motif by protein kinase D (PKD). 3 There is no additional potential site for PKD-mediated phosphorylation and no potential Ser-phosphorylation site for protein kinase C (PKC) (K/R X S/T X K/R).
The central basic domain and the helix-span-helix motif mediate DNA binding of AP2␣. 4, 5 These domains mediate forming hetero-and homo-dimers of AP2, and this dimerization is required for the DNA binding activity. The prolineand glutamine-rich domain at the N terminus is responsible for transactivation. Therefore, the functional phosphorylation site may be located in this region. Referring to supplemental Figure I , Ser258 is in the basic domain conserved among species, and all 5 subtypes of AP2␣, ␤, ␦, ␥, and and Ser326 was also found conserved in the helix-span-helix motif, corresponding to 247 and 315 in xenopus AP2␣ that are also in a PKD phosphorylation motif. 4, 5 Interestingly, the LXRXXS (Ser277) motif of the AP2␤ basic domain is completely identical to that of AP2␣, and AP2␤ was shown to directly bind to the adiponectin promoter and inhibit its transcriptional activity. 6 Therefore, it would be rational to hypothesize that PKD is involved in regulation of the AP2mediated gene expression.
PKD is a Ser/threonine (Thr) kinase, 7,8 activated by cellgrowth promoting reagents such as phorbol 12-myristate 13-acetate (PMA), platelet derived growth factor (PDGF), and G protein-coupled receptor (GPCR) ligands. 9 -12 It seems related to cell proliferation, as overexpression of PKD increases DNA synthesis and cell growth, 13 and stimulates the Raf-MEK-extracellular signal regulated kinase (ERK) path-way through the RIN1 phosphorylation. 14 AP2␣ is also associated with cell proliferation and differentiation. AP2␣deficient fibroblasts grow slower than the wild type. 15 AP2␣ level decreases in some carcinoma cells. 5, 16, 17 AP2␣ positively regulates the proto-oncogene c-erb-B2 expression. 18 Both PKD and AP2␣ could thus be related to the gene expression to regulate cellular growth and proliferation, and therefore PKD-mediated Ser-phosphorylation is a good candidate mechanism for regulation of this system.
In this study, we intended to identify the functional Ser-phosphorylation site of AP2␣ and to examine whether modulation of this system influences HDL metabolism hoping that AP2 signaling would be a new target for prevention of atherosclerosis.
Materials and Methods
Monoclonal antibody against human and mouse ABCA1 (MABI98-7) 19 was generated in rats at MAB Institute (Yokohama, Japan) by using a peptide CNFAKDQSDDDHLKDLSLHKN representing the amino acid sequence of the C terminus of human and mouse ABCA1. Apolipoprotein A-I (apoA-I) was isolated from human plasma HDL. 20 For luciferase reporter gene assay, ABCA1 promoter constructs were generated by polymerase chain reaction (PCR). 1 The plasmid for expression of pSG-neo-AP2␣ and the control vector 21 were kindly provided by Dr M. A. Tainsky (Wayne State University, Detroit, Mich). To introduce mutation of Ser to Ala into AP2␣ protein at the residues 258 or 326, site-directed mutation was introduced by using a Quick Change II Site-Directed Mutagenesis kit (Stratagene). Other general experimental procedures are available in the online supplemental materials.
Results

Phosphorylation of AP2␣ by PKD Regulates Its Binding to ABCA1 Promoter
Doxazosin that upregulated apoA-I-mediated cellular lipid release and increased mouse plasma HDL 1 did not influence AP2␣ phosphorylation at the PKA-specific site ( Figure 1A ). On the other hand, it reduced AP2␣ phosphorylation by PKD in dose-dependent fashion ( Figure 1B ). PMA increased AP2␣ phosphorylation by PKD but not that by PKC and doxazosin inhibited this action of PMA in HEK293 cells AP2␣ was transfected to ( Figure 1C ). Thus, phoshorylation of AP2␣ at a PKD-specific site(s) is involved in the doxazosin-related reactions.
Mutation to Ala was introduced at either or both of PKD phosphorylation sites of Ser258 and Ser326 in the glutathione S-transferase (GST)-AP2␣ fusion protein (Figure 2A ). Wildtype GST-AP2␣ and GST-AP2␣(S326A) proteins were phosphorylated by PKD. Phosphorylation of GST-AP2␣(S258A) was less and phosphorylation of GST-AP2␣(S258/326A) was undetectable ( Figure 2B ). The results showed that Ser258 is more efficiently phosphorylated by PKD.
DNA binding activity of the AP2␣ mutants was examined. The antibody equally recognizes both AP2␣ and AP2␣(S258A) in HEK 293 cells (data not shown). As shown in Figure 3A by gel shift assay, PKD reaction increased the DNA binding of wild-type AP2␣ but not AP2␣(S258A). Chromatin immunoprecipitation (ChIP) analysis also demonstrated tight interaction of wild-type AP2␣ but not that of AP2␣(S258A), which were transfected to HepG2 cells which lack endogenous AP2␣, 22 together with the ABCA1 promoter containing the AP2 binding site ( Figure 3B ). Figure 3C shows inhibitory effect of AP2␣ and its mutants AP2␣(S258A), AP2␣(S326A), and AP2␣(S258A/S326A) on the ABCA1 promoter activity. The inhibition by AP2␣ was reduced by mutation at Ser258. The results confirmed that phosphorylation of AP2␣ at Ser258 is essential for its binding to DNA and regulating the transcriptional activity.
Regulation by PKD of ABCA1 Activity and Other AP2-Regulated Genes
The small interfering (si) RNA treatment significantly reduced the PKD protein level and increased ABCA1 protein expression in THP-1 macrophage. It did not influence expression of AP2␣, but its phosphorylation by PKD was strongly inhibited ( Figure 4A ). ABCA1 mRNA expression was also significantly increased by knockdown of PKD ( Figure 4B ). ABCA1 promoter activity was also upregulated by PKD-siRNA for the wild-type promoter in HEK293. Increase of the transcription activity was more prominent (by 100%) with the promoter of Ϫ369 to ϩ110 (data not shown). On the other hand, its basic activity was increased, and the effect of siRNA was negative when the AP2 binding site of the promoter was mutated ( Figure 4C ). Knockdown of PKD increased the apoA-I-mediated free cholesterol release from THP-1 macrophage ( Figure 4D ). The results thus demonstrated that PKD inhibition decreased the AP2␣ activity for DNA binding, increased ABCA1 expression and enhanced the HDL biogenesis.
Effects of Protein Kinase Inhibitors on PKD in Cells and In Vivo
Doxazosin inhibited PKD-mediated AP2␣ phosphorylation in the mouse liver ( Figure 5A ), so that inhibition of PKD in vivo was attempted in mouse. Specific inhibitors for PKD are currently unavailable. PKD is activated through PKCmediated phosphorylation of Ser744 and Ser748, [23] [24] [25] so that PKC inhibitors such as Gö6983, Gö6976, rottlerin, and doxazosin were tested for modulation of the PKD phosphorylation. Gö6983 most strongly and selectively inhibited PKD, whereas others did only moderately to generate consistent results with those by PKD siRNA, so that this compound was chosen for the in vivo study (these data are provided in supplemental Figures II and III) . Gö6983 inhibited phosphorylation of PKD and AP-2␣ in the liver in mice, but not phosphorylation of proteins that were identified by using an antiphospho-PKC-substrate antibody (Figure 5B , 5C, and 5D). Gö6983 inhibited expression of SREBP1 in the liver, whereas it had no effect on SREBP2 in the liver and SREBP1 in the adipose tissue ( Figure 5E ).
Finally, we investigated whether PKD inhibition increases expression of the ABCA1 gene in vivo and thus leads to raising HDL level in plasma. As shown in Figure 6A , the mRNA and protein levels of ABCA1 were both increased in the liver by the Gö6983 treatment. High-performance liquid chromatography (HPLC) analysis of plasma demonstrated significant increase of HDL ( Figure 6B and supplemental  Table) . Gö6983 also decreased plasma triglyceride, being consistent with the decrease of SREBP1 expression. . PKD phosphorylates AP2␣ Ser258 to increase DNA binding and suppress ABCA1 promoter activity. A, Gel shift assay for the AP2-binding site in the ABCA1 promoter for AP2␣ and AP2␣(S258A) proteins in the presence and absence of the PKD catalytic subunit. B, ChIP assay for DNA binding. HepG2 cells that lack endogenous AP2␣ were transfected with AP2␣ and AP2␣(S258A). Nuclear proteins cross-linked with DNA were immunoprecipitated by ant-AP2␣ antibody and PCR was performed for the AP2 binding site. C, ABCA1 promoter activity assay. ABCA1 promoter construct (WT-Luc) and AP2␣ were transfected to HEK293 cells. Luciferase activity was normalized for phRL-TK. *** indicates difference with PϽ0.001 from mock. Figure 4 . PKD-knockdown and ABCA1 expression/HDL biogenesis. A, PKD was knocked-down in THP-1 macrophages by siRNA, and cell protein (50 g) was analyzed by Western blotting. Immunoprecipitatant with anti-AP2␣ antibody was analyzed by antiphospho-PKD substrate antibody. B, THP-1 cells were similarly treated and ABCA1 mRNA was analyzed. C, Activity of ABCA1 reporter construct of wild-type (WT-luc) and its AP2 binding site mutant (AP2m-luc) was measured in HEK293 cells with PKD-knockdown. D, THP-1 macrophages treated as above were incubated with apoA-I, and cholesterol release was measured. Data represent averageϮSD for triplicate assays. *PϽ0.05, **PϽ0.01, ***PϽ0.001 against scramble controls.
Discussion
ABCA1 is a rate-limiting factor of plasma HDL level as it "catalyzes" HDL biogenesis. 26 This is an important part of body and cellular cholesterol homeostasis because cholesterol is not catabolized in extrahepatic peripheral cells except for steroidogenesis and therefore transported to the liver by HDL for conversion to bile acids. 26 This view is consistent with clinical findings that HDL is an apparent negative risk factor for atherosclerosis. Accordingly, increase of the ABCA1 activity may be an effective approach for prevention and cure of atherosclerosis. In the present study, we investigated molecular mechanism for negative regulation of ABCA1 gene expression by AP2␣, expecting that this reaction may be a good pharmacological target for the increase of HDL biogenesis.
Based on our finding that Ser-phosphorylation of AP2␣ was associated with its binding activity to the ABCA1 promoter, 1 potential sites for Ser-phosphorylation was analyzed in AP2␣ protein. Phosphorylation by PKD mainly at Ser258 was found related to the DNA binding activity of AP2␣. The results are consistent with the previous findings that the region of this residue is included in the highly conserved basic domain of AP2␣ considered responsible for the binding to DNA after the dimerization mediated by the helix-span-helix domain. 4, 5 From the results, however, minor involvement of Ser326 has not been excluded.
Doxazosin reduced phosphorylation of this specific site, decreased binding of AP2␣ to the ABCA1 promoter, and increased its transcription. Direct inhibition of PKD expression by siRNA resulted in the increase of ABCA1 expression and of biogenesis of HDL. Pharmacological inhibition of PKD also increased ABCA1 expression and its activity. Several mechanisms were proposed for posttranscriptional regulation of AP2␣ activity in previous reports, such as PKA-mediated phosphorylation, 2 redox regulation, 27 and sumoylation. 28 Physical interaction with various proteins was also indicated for modulation of the AP2␣ activity. 5 However, this study demonstrated that phosphorylation of a specific site(s) by PKD modulates AP2 binding to a specific site of DNA and its functional activity. PKA-phosphorylation was not investigated in detail in the present study, as PKA-phosphorylation did not seem affected by doxazosin. Also, it was previously shown that PKA-phosphorylation at Ser-239 does not influence DNA-binding of AP2␣. 2 In addition, cAMP and therefore PKA activation has been indicated for ABCA1 upregulation rather than downregulation. Therefore, it is very unlikely that the Ser-239 phosphor- Figure 6 . Effect of PKD inhibition by Gö 6983 in mouse. A, Expression of ABCA1 in the liver. Total RNA (50 ng) from the liver tissue (30 mg wet weight) was used for ABCA1 mRNA, and 50 g protein was analyzed by Western blotting for ABCA1 protein. B, Plasma lipoprotein. Blood plasma was analyzed for lipoproteins by HPLC by monitoring total (TC) and free (FC) cholesterol, choline-phospholipids (PL), and triacylglycerol (TG). *PϽ0.05 and **PϽ 0.01. Figure 5 . Effect of PKD inhibition in mice. A, PKD-mediated phosphorylation in the liver in doxazosin (Dox)-treated C57BL/6 mice (nϭ3 for each group). B, C, and D, Gö 6983 or vehicle (C) was given to the mice (nϭ7 for each group). Liver protein (750 g) immunoprecipitated with anti-AP2␣ antibody was analyzed with antibodies against phospho-Ser (pSer) and AP2␣ (Ap2) (B). Liver protein (5 g) was analyzed by Western blotting with antibodies against phospho-PKD (pPKD) and PKD (C), and phospho-PKC␣ (pPKC␣), PKC␣, and phospho-PKC substrate (pPKC-substrate) (D). E, Expression of SREBP1 and SREBP2 in the liver and SREBP1 in the adipose tissue by measuring mRNA. The graphs represent quantified blotting data of at least 3 experiments. *PϽ0.05 and **PϽ 0.01. ylation is involved in negative regulation of ABCA1 transcription via PKD/AP2␣ pathway. However, additional studies focusing on specific PKA-phosphorylation sites and ABCA1 expression should be required for complete exclusion of its involvement.
PKD was initially identified as a novel PKC-related enzyme PKC, 29 and later recognized as a new family of protein kinase. Its catalytic domain is not exactly similar to the conserved kinase domain of other PKC members but rather resembles that of calcium/calmodulin dependent kinases. 30 Many mediators to activate PKC also activate PKD, such as PMA, DAG, PDGF, oxdative stress, and several GPCR ligands (thrombin, serotonin, bradykinin, and lysophosphatidic acid). 9 -12,31 It has recently been reported that PKD is activated by its phosphorylation of Ser744 and Ser748 mainly by PKC as it is blocked by PKC inhibitors including Gö6983. 25 It is interesting that Gö6983 more effectively inhibited PKD reaction than PKC-mediated reactions in cells and in vivo, in comparison to other compounds, in spite of the fact that its inhibitory activity is much stronger against PKC than against PKD. 32 We therefore chose Gö6983 for selective inhibition of PKD for this empirical reason. This compound in fact reproduced the effects of doxazosin in mice to increase ABCA1 expression and plasma HDL ( Figure 6 and supplemental Table I ).
PKD may also be involved in negative regulation of the adiponectin gene by AP2␤, 6 as LRRAKS motif is conserved for AP2␣ and AP2␤ in their DNA binding domain. Overexpression of AP2␤ caused lipid accumulation and cellular enlargement in adipocytes. 6 Being consistent with these findings, our preliminary experimental observation showed that knockdown of PKD by siRNAs increased adiponectin mRNA in NIH3T3-L1 adipocytes and transcriptional activity of its promoter. PKD knockdown in the adipocyte decreased lipid droplet size shown by oil red O staining. Finally, PKD inhibition by Gö6983 in vivo resulted in increase of mRNA and plasma level of adiponectin. Lipid accumulation of adipocytes was decreased by the PKD knockdown.
PKD siRNA decreased SREBP1, an adipogenesisregulating gene, but not SREBP2, a cholesterol homeostasisregulating gene (Iwamoto et al, 2008 unpublished data) . Inhibition of PKD by Gö6983 in vivo significantly diminished SREBP1 expression in the liver ( Figure 5E ) and presumably caused reduction of plasma triglyceride in mice (supplemental Table) . A more recent report that inhibition of PKD increases release of lipoprotein lipase by cardiomyocytes may be consistent with these findings. 33 PKD mediates mitogenic response to various growth factors, and potentiated cellular DNA synthesis by increasing duration of MEK/ERK/RSK signaling. 13, 34 Furthermore, PKD enhanced antiapoptotic genes by activation of NF-B through the IKB degradation in response to oxidative stress-PKD was required for cellular survival after oxdative stress-induced apoptosis. 31 Several other reports showed that doxazosin downregulated NF-B signaling and induced apoptosis in some types of cells. [35] [36] [37] These findings are not inconsistent with our results of inhibition of PKD and AP2␣ phosphorylation by doxazosin.
Function of AP2 was generally related to cell proliferation, differentiation, and apoptosis. Fibroblast derived from AP2␣deficient mouse exhibited growth-retardation indicating its requirement for cell proliferation perhaps by suppressing the genes for terminal differentiation, apoptosis, and growth retardation. 15 Increased AP2 levels have been shown in various types of cancer cells. 16, 17, 38 The proto-oncogene c-erb-B2 expression has been reported regulated by AP2. 18 Among various subtypes of AP2, PKD recognition sites are well conserved. PKD knock-down by siRNA in HeLa cells decreased c-erb-B2 mRNA expression and cell proliferation rate (Iwamoto et al, 2008 unpublished data). Thus, PKD/AP2 signaling could regulate the balance of cell growth. During proliferation, cholesterol is required for cells to generate new membrane, and ABCA1 should perhaps be downregulated to prevent cholesterol from wasteful release. Therefore, action of AP2␣ on expression of the ABCA1 gene and HDL biogenesis may be consistent with other general function of this transcription factor for enhancing cell proliferation. In agreement with this view, PDGF reportedly increases 3-hydroxy-3-methylglutaryl (HMG)-coenzyme A (CoA) synthesis 39 and low-density lipoprotein receptor activity, 40 and decreases ABCA1 expression level. 41 Inhibition of cellular cholesterol biosynthesis by statins reduces proliferation of cancer cells. 42 It is also consistent with the finding that cellular free cholesterol doubled following the S-phase, and reached its maximum well before mitosis 43 by the increase of its uptake from extracellular lipoproteins and by the reduction of its release.
The potential scheme achieved by inhibition of the PKD/ AP2 pathway is illustrated in supplemental Figure IV . This process would increase ABCA1, HDL, and adiponection and improve such multiple risk status defined as "metabolic syndrome." A question remains regarding what is a trigger for PKD/AP2␣ signal for regulation of the ABCA1 gene expression. Further investigation is needed to address this question, perhaps in the relation to regulation of cell growth.
In conclusion, we demonstrated that PKD phosphorylates Ser258 of AP2␣ and increases the DNA binding of AP2␣ protein. Inhibition of PKD/AP2␣ signaling pathway therefore decreases repression of the ABCA1 gene expression and accordingly increases ABCA1 and biogenesis of HDL. This finding is consistent with the other AP2-regulated gene, adiponectin. Inhibition of PKD thus would be a new drug target for prevention of atherosclerosis.
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